Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers (Protocol 3)Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers (Protocol 2)This Study is to Determine if Degenerative Spinal Pain and Disorders Cause the Levels of Substance P to Change in a Patients Saliva, Blood and/or Cerebrospinal Fluid.Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 1Role of Substance P in Post-Traumatic Stress DisorderEvaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQMeasurement of Substance P in Saliva of Low Back Pain PatientsThe Effect of Beta-blockers in Substance P Levels and the Swallowing FunctionEffect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary SyndromeEffect of Urocortins in Patients With Heart FailureA Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaNeuropeptides and Venous Pelvic PainA Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable PainA Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance PLidocaine on Pain Relief and IL and Substance P in FibromyalgiaPharmacogenetics of Ace Inhibitor-Associated AngioedemaEffects of Substance P Antagonists on Adrenal SecretionOrvepitant (GW823296) in Adult Post Traumatic Stress DisorderNeurokinin Receptor Antagonist Associated to Ondansetron in PONVReduction of IgE Antibody in Human Allergic SubjectsPositron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic CancerStudy to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate AsthmaSubstance P Antagonist in the Treatment of Posttraumatic Stress DisorderEfficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell TransplantationSputum and Plasma Levels of Nociceptin and Substance P in Patients With Asthma, COPD and Chronic CoughRegional Anaesthesia and Substance P in Head and Neck CancerImportance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain InjuryDifferentiating the Effects of Substance P and Beta-endorphinThe Role of Substance P on Perception of Breathlessness During Resistive Load BreathingNeuropeptide Therapy of Recent Onset Type 1 DiabetesNeurokinin-1 Receptor Antagonist for the Treatment of Itch in EB PatientsSubstance P as a Biomarker to Evaluate the Reduction of Multiple Immunization Pain
P4844
P688
Q61936528-CB16F169-048D-4917-BE8A-8ABB054FB4B7Q61936529-5FD72B24-76A4-455A-9034-947478707879Q61965831-D85D22E9-06F5-4E33-B483-B1E5AE2E1804Q62035236-84EDE53E-741C-45A9-BF64-3E59D6863F2EQ62106444-763CC184-E068-4B9E-B488-ABF9AEB8B08BQ62110156-1808F479-A319-4BCD-9C9B-0DFB5233BC45Q63063404-2B84C67C-9EBB-4D09-954D-C0C6C56D6939Q63811436-943DB51F-D3E2-49C2-96C9-51EF46A35E12Q63839146-6996B04E-FF83-450C-A1DA-F688FF5BB283Q63844227-DE2086CE-381F-4814-896B-DB1A42041AE8Q64122365-81E415A9-F423-4646-930D-3268532B5E75Q64185843-B6EBC270-05FA-4BF0-B7FB-78A27C556B73Q64397392-AC2D8C5C-2FC1-433A-9AB7-6DF424AB3ACDQ64610278-AE8325D3-2082-42FD-939B-B8207999D5FAQ64622454-8A07D4CA-8C9D-4321-B8D8-4C9D3E33D32CQ64650094-96F8589C-0281-470B-A055-8397F14140DCQ64660382-B2B8E9A2-566A-4FD6-B415-22B49B5F4A17Q64662984-A45650CD-CFCD-4875-AC6A-B16D468CB5E8Q64693072-B385C46E-DBB0-4D11-A0A9-A09BA24D868CQ65349193-DF370265-F9F6-4F2D-98A7-A042BCBBED8DQ65375730-D8E1EAAC-E6BD-498A-B787-863AE01700E6Q65379183-FB4489F1-D549-48FD-B8C0-59987FABA7C7Q65380224-C49357D6-EB71-4131-97A4-B8B2F5E3CC50Q65387513-5D0CBCC1-6B1F-42BE-B426-649F26AB109BQ65391258-BD346F57-92B5-4B20-9E22-F52C425BDFDAQ66027101-0062195E-5F21-4DAB-9E06-683DF39F5C1AQ66072815-B872B4E8-98B5-4B42-8E88-812A8FD088A9Q66075446-DF9D4CED-67F5-4B25-9256-3F1A9F5C9C33Q66343040-F815F925-0C5B-4760-866B-6162F75D1442Q66347347-9866D653-2947-4525-8997-4F94F401585BQ66398898-4F47B59C-51B2-479F-9D3B-615DFE5757FAQ66409185-40FC6652-2036-4CFB-A32D-2124CF2AB26DQ74280810-7B259C47-6092-47C0-87EF-DFE8B221862F
P4844
description
Protein
@de
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Neurochinina A
@it
Neurokinin A
@de
Neurokinin A
@fr
Neurokinin A
@nl
Neurokinin A
@sh
Neurokinin A
@sr
Neurokinin A
@sr-el
neurokinin A
@en
Неурокинин А
@sr-ec
نئوروکینین آ
@azb
type
label
Neurochinina A
@it
Neurokinin A
@de
Neurokinin A
@fr
Neurokinin A
@nl
Neurokinin A
@sh
Neurokinin A
@sr
Neurokinin A
@sr-el
neurokinin A
@en
Неурокинин А
@sr-ec
نئوروکینین آ
@azb
altLabel
C50H80N14O14S
@it
NKA
@en
Neurokinin K
@sr
Neuropeptid K
@sr
Neuropeptid gama
@sr
Sostanza K
@it
Substanz K
@de
Supstanca K
@sr
TAC1(98-107)
@en
neuromedin L
@en
prefLabel
Neurochinina A
@it
Neurokinin A
@de
Neurokinin A
@fr
Neurokinin A
@nl
Neurokinin A
@sh
Neurokinin A
@sr
Neurokinin A
@sr-el
neurokinin A
@en
Неурокинин А
@sr-ec
نئوروکینین آ
@azb
P31
P361
P486
P592
P6366
P638
P661
P662
P683
P2067
1,132.569914
P231
86933-74-6
P233
CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC ...... O)C(CCCCN)NC(=O)C(CC2=CN=CN2)N
P235
HEAUFJZALFKPBA-UHFFFAOYSA-N
P274
C₅₀H₈₀N₁₄O₁₄S
P2868
P2888
P373
Neurokinin A
P3937
R-HSA-380131
P486
P592
CHEMBL217406